Focusing sharply on its core business resulted in a 68 per cent compound annual growth rate (CAGR), reducing adjusted negative EBITDA from Rs 162 crore to Rs 17 crore
Read More
In recent years, advancements in medical technology and surgical interventions have revolutionised the management of advanced heart failure, offering hope and improved outcomes for patients facing end-stage cardiac conditions
Read More
